Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice

Caitlin M. Nealon, Angela N. Henderson-Redmond, David E. Hale, Daniel Morgan

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB 1 ) following prolonged administration. Desensitization results from phosphorylation of CB 1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mice expressing a mutant form of CB 1 , in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Tolerance to the antinociceptive effects of WIN55,212-2 was delayed in S426A/S430A mutants using the tail-flick and formalin tests. However, tolerance to the antinociceptive effects of once daily CP55,940 injections was not significantly delayed in S426A/S430A mutant mice using either of these tests. Interestingly, the dose response curve shifts for the hypothermic and antinociceptive effects of CP55,940 that were induced by chronic treatment with this agonist in wild-type mice were blocked in S426A/S430A mutant mice. Assessment of mechanical allodynia in mice exhibiting chronic cisplatin-evoked neuropathic pain found that tolerance to the anti-allodynic effects WIN55,212-2 but not CP55,940 was delayed in S426A/S430A mice compared to wild-type littermates. Despite these deficits in tolerance, S426A/S430A mutant mice eventually developed tolerance to both WIN55,212-2 and CP55,940 for all pain assays that were examined, suggesting that other mechanisms likely contribute to tolerance for these cannabinoid agonists. These findings suggest that GRK- and βarrestin2-mediated desensitization of CB 1 may strongly contribute to the rate of tolerance to the antinociceptive effects of WIN55,212-2, and raises the possibility of agonist-specific mechanisms of cannabinoid tolerance.

Original languageEnglish (US)
Pages (from-to)151-159
Number of pages9
JournalNeuropharmacology
Volume148
DOIs
StatePublished - Apr 1 2019

Fingerprint

Cannabinoid Receptors
Cannabinoid Receptor Agonists
G-Protein-Coupled Receptor Kinase 1
Phosphorylation
Arrestin
Dronabinol
Cannabinoids
Hyperalgesia
Neuralgia
Pain Measurement
Psychologic Desensitization
Alanine
Serine
Cisplatin
Tail
Pain
Injections
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Cellular and Molecular Neuroscience

Cite this

Nealon, Caitlin M. ; Henderson-Redmond, Angela N. ; Hale, David E. ; Morgan, Daniel. / Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice. In: Neuropharmacology. 2019 ; Vol. 148. pp. 151-159.
@article{8d94c6ebcb74447e91320e0d612ac4d0,
title = "Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice",
abstract = "Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB 1 ) following prolonged administration. Desensitization results from phosphorylation of CB 1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mice expressing a mutant form of CB 1 , in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Tolerance to the antinociceptive effects of WIN55,212-2 was delayed in S426A/S430A mutants using the tail-flick and formalin tests. However, tolerance to the antinociceptive effects of once daily CP55,940 injections was not significantly delayed in S426A/S430A mutant mice using either of these tests. Interestingly, the dose response curve shifts for the hypothermic and antinociceptive effects of CP55,940 that were induced by chronic treatment with this agonist in wild-type mice were blocked in S426A/S430A mutant mice. Assessment of mechanical allodynia in mice exhibiting chronic cisplatin-evoked neuropathic pain found that tolerance to the anti-allodynic effects WIN55,212-2 but not CP55,940 was delayed in S426A/S430A mice compared to wild-type littermates. Despite these deficits in tolerance, S426A/S430A mutant mice eventually developed tolerance to both WIN55,212-2 and CP55,940 for all pain assays that were examined, suggesting that other mechanisms likely contribute to tolerance for these cannabinoid agonists. These findings suggest that GRK- and βarrestin2-mediated desensitization of CB 1 may strongly contribute to the rate of tolerance to the antinociceptive effects of WIN55,212-2, and raises the possibility of agonist-specific mechanisms of cannabinoid tolerance.",
author = "Nealon, {Caitlin M.} and Henderson-Redmond, {Angela N.} and Hale, {David E.} and Daniel Morgan",
year = "2019",
month = "4",
day = "1",
doi = "10.1016/j.neuropharm.2018.12.026",
language = "English (US)",
volume = "148",
pages = "151--159",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",

}

Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice. / Nealon, Caitlin M.; Henderson-Redmond, Angela N.; Hale, David E.; Morgan, Daniel.

In: Neuropharmacology, Vol. 148, 01.04.2019, p. 151-159.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tolerance to WIN55,212-2 is delayed in desensitization-resistant S426A/S430A mice

AU - Nealon, Caitlin M.

AU - Henderson-Redmond, Angela N.

AU - Hale, David E.

AU - Morgan, Daniel

PY - 2019/4/1

Y1 - 2019/4/1

N2 - Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB 1 ) following prolonged administration. Desensitization results from phosphorylation of CB 1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mice expressing a mutant form of CB 1 , in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Tolerance to the antinociceptive effects of WIN55,212-2 was delayed in S426A/S430A mutants using the tail-flick and formalin tests. However, tolerance to the antinociceptive effects of once daily CP55,940 injections was not significantly delayed in S426A/S430A mutant mice using either of these tests. Interestingly, the dose response curve shifts for the hypothermic and antinociceptive effects of CP55,940 that were induced by chronic treatment with this agonist in wild-type mice were blocked in S426A/S430A mutant mice. Assessment of mechanical allodynia in mice exhibiting chronic cisplatin-evoked neuropathic pain found that tolerance to the anti-allodynic effects WIN55,212-2 but not CP55,940 was delayed in S426A/S430A mice compared to wild-type littermates. Despite these deficits in tolerance, S426A/S430A mutant mice eventually developed tolerance to both WIN55,212-2 and CP55,940 for all pain assays that were examined, suggesting that other mechanisms likely contribute to tolerance for these cannabinoid agonists. These findings suggest that GRK- and βarrestin2-mediated desensitization of CB 1 may strongly contribute to the rate of tolerance to the antinociceptive effects of WIN55,212-2, and raises the possibility of agonist-specific mechanisms of cannabinoid tolerance.

AB - Tolerance to cannabinoid agonists can develop through desensitization of the cannabinoid receptor 1 (CB 1 ) following prolonged administration. Desensitization results from phosphorylation of CB 1 by a G protein-coupled receptor kinase (GRK), and subsequent association of the receptor with arrestin. Mice expressing a mutant form of CB 1 , in which the serine residues at two putative phosphorylation sites necessary for desensitization have been replaced by non-phosphorylatable alanines (S426A/S430A), display reduced tolerance to Δ 9 -tetrahydrocannabinol (Δ 9 -THC). Tolerance to the antinociceptive effects of WIN55,212-2 was delayed in S426A/S430A mutants using the tail-flick and formalin tests. However, tolerance to the antinociceptive effects of once daily CP55,940 injections was not significantly delayed in S426A/S430A mutant mice using either of these tests. Interestingly, the dose response curve shifts for the hypothermic and antinociceptive effects of CP55,940 that were induced by chronic treatment with this agonist in wild-type mice were blocked in S426A/S430A mutant mice. Assessment of mechanical allodynia in mice exhibiting chronic cisplatin-evoked neuropathic pain found that tolerance to the anti-allodynic effects WIN55,212-2 but not CP55,940 was delayed in S426A/S430A mice compared to wild-type littermates. Despite these deficits in tolerance, S426A/S430A mutant mice eventually developed tolerance to both WIN55,212-2 and CP55,940 for all pain assays that were examined, suggesting that other mechanisms likely contribute to tolerance for these cannabinoid agonists. These findings suggest that GRK- and βarrestin2-mediated desensitization of CB 1 may strongly contribute to the rate of tolerance to the antinociceptive effects of WIN55,212-2, and raises the possibility of agonist-specific mechanisms of cannabinoid tolerance.

UR - http://www.scopus.com/inward/record.url?scp=85060337231&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060337231&partnerID=8YFLogxK

U2 - 10.1016/j.neuropharm.2018.12.026

DO - 10.1016/j.neuropharm.2018.12.026

M3 - Article

C2 - 30629988

AN - SCOPUS:85060337231

VL - 148

SP - 151

EP - 159

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

ER -